# Beam Therapeutics Fundamentals

BEAM | Stock | ## USD 43.61 0.43 1.00% |

Beam Therapeutics fundamentals help investors to digest information that contributes to Beam Therapeutics' financial success or failures. It also enables traders to predict the movement of Beam Therapeutics Stock. The fundamental analysis module provides a way to measure Beam Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Beam Therapeutics stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Beam Therapeutics | Select Account or Indicator |

**M**this year, although the value of Earning Before Interest and Taxes EBIT will most likely fall to (380.4

**M**).

## Beam Therapeutics Current Ratio Analysis

Beam Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.## Beam Therapeutics Current Ratio | ## 6.43 |

Current Ratio | = | Current Asset Current Liabilities |

## Current Beam Therapeutics Current Ratio | 4.64 X |

Most of Beam Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Beam Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Beam Therapeutics Current Ratio Historical Pattern

Today, most investors in Beam Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Beam Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Beam Therapeutics current ratio as a starting point in their analysis.

Beam Therapeutics Current Ratio |

Share

Timeline |

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Compare to competition |

## Beam Therapeutics Net Cash Flow from Operations

## Net Cash Flow from Operations | ## (71.5 Million) |

In accordance with the recently published financial statements, Beam Therapeutics has a Current Ratio of 4.64 times. This is 59.45% higher than that of the Healthcare sector and 33.71% lower than that of the Biotechnology industry. The current ratio for all United States stocks is 114.81% lower than that of the firm.

## Beam Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Beam Therapeutics's current stock value. Our valuation model uses many indicators to compare Beam Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Beam Therapeutics competition to find correlations between indicators driving Beam Therapeutics's intrinsic value. More Info.Beam Therapeutics is rated**second**in price to book category among related companies. It is rated

**third**in shares outstanding category among related companies creating about 16,542,254 of Shares Outstanding per Price to Book. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Beam Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Beam Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Beam Therapeutics' earnings, one of the primary drivers of an investment's value.

## Beam Therapeutics Price to Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beam Therapeutics' direct or indirect competition against its Price to Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beam Therapeutics could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics of similar companies.Beam Therapeutics is currently under evaluation in price to earnings to growth category among related companies.

## Beam Therapeutics Fundamentals

Return On Equity | (40.23) % | |||

Return On Asset | (7.88) % | |||

Operating Margin | (157.90) % | |||

Current Valuation | 2.13 B | |||

Shares Outstanding | 70.47 M | |||

Shares Owned by Insiders | 1.85 % | |||

Shares Owned by Institutions | 87.07 % | |||

Number of Shares Shorted | 13.01 M | |||

Price to Earning | 37.48 X | |||

Price to Book | 4.26 X | |||

Price to Sales | 33.93 X | |||

Revenue | 91.95 M | |||

Gross Profit | (180.29 M) | |||

EBITDA | (145.19 M) | |||

Net Income | (315.45 M) | |||

Cash and Equivalents | 1.09 B | |||

Cash per Share | 15.90 X | |||

Total Debt | 178.5 M | |||

Debt to Equity | 0.25 % | |||

Current Ratio | 4.64 X | |||

Book Value Per Share | 10.38 X | |||

Cash Flow from Operations | 93.55 M | |||

Short Ratio | 13.39 X | |||

Earnings Per Share | (3.59) X | |||

Price to Earnings To Growth | (2.30) X | |||

Number of Employees | 507 | |||

Beta | 1.66 | |||

Market Capitalization | 3.12 B | |||

Total Asset | 8.58 B | |||

Retained Earnings | (208.39 M) | |||

Working Capital | 2.18 B | |||

Current Asset | 2.89 B | |||

Current Liabilities | 706.6 M | |||

Z Score | 10.2 |

## About Beam Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Deferred Revenue | 348.6 M | 284.5 M | |

Revenues | 51.8 M | 55.9 M | |

Revenue to Assets | 0.035162 | 0.0379 | |

Revenue Per Employee | 152 K | 164 K |

## Beam Therapeutics Investors Sentiment

The influence of Beam Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Beam Therapeutics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Beam Therapeutics' public news can be used to forecast risks associated with investment in Beam Therapeutics. The trend in average sentiment can be used to explain how an investor holding Beam Therapeutics can time the market purely based on public headlines and social activities around Beam Therapeutics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Beam Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Beam Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Beam Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Beam Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Beam Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Beam Therapeutics' short interest history, or implied volatility extrapolated from Beam Therapeutics options trading.

## Pair Trading with Beam Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Beam Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Beam Therapeutics will appreciate offsetting losses from the drop in the long position's value.### Moving against Beam Therapeutics

- | 0.68 | AZO | Autozone | Earnings Call This Week | PairCorr |

The ability to find closely correlated positions to Beam Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Beam Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Beam Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Beam Therapeutics to buy it.

The correlation of Beam Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Beam Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Beam Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Beam Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Continue to Beam Therapeutics Piotroski F Score and Beam Therapeutics Altman Z Score analysis. Note that the Beam Therapeutics information on this page should be used as a complementary analysis to other Beam Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

## Complementary Tools for Beam Therapeutics Stock analysis

When running Beam Therapeutics price analysis, check to measure Beam Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beam Therapeutics is operating at the current time. Most of Beam Therapeutics' value examination focuses on studying past and present price action to predict the probability of Beam Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Beam Therapeutics' price. Additionally, you may evaluate how the addition of Beam Therapeutics to your portfolios can decrease your overall portfolio volatility.

Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | Go | |

Equity ValuationCheck real value of public entities based on technical and fundamental data | Go | |

Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | Go | |

Equity ValuationCheck real value of public entities based on technical and fundamental data | Go | |

Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go |

Is Beam Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 3 B | Quarterly Revenue Growth YOY 19.71 | Return On Assets (0.08) | Return On Equity (0.40) |

The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Beam Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.